Study Details
A long term study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia converted from Erythropoieses Stimulating Agent (ESA) treatment
Clinicaltrials.gov ID
Astellas Study ID
1517-CL-0312
EudraCT ID
N/A
Condition
Dialysis in Kidney Disease with Anemia
Phase
Phase 3
Age
20 years - N/A
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
May 2016 - Nov 2017
Masking
None (Open Label)
Enrollment number
164
A Phase 3, Long-term study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia converted from erythropoiesis stimulating agent treatment
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A long term study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia converted from Erythropoieses Stimulating Agent (ESA) treatment? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site JP00018
Hokkaido, Japan
Site JP00004
Gunma, Japan
Site JP00005
Fukuoka, Japan
Site JP00002
Nagano, Japan
Site JP00009
Shizuoka, Japan
Site JP00020
Ishikawa, Japan
Site JP00001
Yamaguchi, Japan
Site JP00022
Kumamoto, Japan
Site JP00016
Kyoto, Japan
Site JP00010
Kumamoto, Japan
Site JP00015
Nagano, Japan
Site JP00025
Osaka, Japan
Site JP00012
Nagano, Japan
Site JP00006
Gunma, Japan
Site JP00021
Hokkaido, Japan
Site JP00023
Hyogo, Japan
Site JP00017
Aichi, Japan
Site JP00014
Tokyo, Japan
Site JP00008
Ibaraki, Japan
Site JP00007
Saitama, Japan
Site JP00024
Kumamoto, Japan
Site JP00019
Hokkaido, Japan
Site JP00013
Tottori, Japan
Site JP00011
Wakayama, Japan
Site JP00003
Niigata, Japan